Cargando…

Clinical Relevance of [(18)F]Florbetaben and [(18)F]FDG PET/CT Imaging on the Management of Patients with Dementia

PET of β-Amyloid plaques (Aβ) using [(18)F]florbetaben ([(18)F]FBB) and [(18)F]fluorodeoxyglucose ([(18)F]FDG) increasingly aid clinicians in early diagnosis of dementia, including Alzheimer’s disease (AD), frontotemporal disease, dementia with Lewy bodies, and vascular dementia. The aim of this ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Librizzi, Damiano, Cabanel, Nicole, Zavorotnyy, Maxim, Riehl, Elisabeth, Kircher, Tilo, Luster, Markus, Hooshyar Yousefi, Behrooz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956266/
https://www.ncbi.nlm.nih.gov/pubmed/33652938
http://dx.doi.org/10.3390/molecules26051282
_version_ 1783664395247681536
author Librizzi, Damiano
Cabanel, Nicole
Zavorotnyy, Maxim
Riehl, Elisabeth
Kircher, Tilo
Luster, Markus
Hooshyar Yousefi, Behrooz
author_facet Librizzi, Damiano
Cabanel, Nicole
Zavorotnyy, Maxim
Riehl, Elisabeth
Kircher, Tilo
Luster, Markus
Hooshyar Yousefi, Behrooz
author_sort Librizzi, Damiano
collection PubMed
description PET of β-Amyloid plaques (Aβ) using [(18)F]florbetaben ([(18)F]FBB) and [(18)F]fluorodeoxyglucose ([(18)F]FDG) increasingly aid clinicians in early diagnosis of dementia, including Alzheimer’s disease (AD), frontotemporal disease, dementia with Lewy bodies, and vascular dementia. The aim of this retrospective analysis was to evaluate clinical relevance of [(18)F]FBB, [(18)F]FDG PET and complimentary CSF measurements in patients with suspected dementia. In this study, 40 patients with clinically suspected or history of dementia underwent (1) measurement of Aβ peptides, total tau, and p-tau protein levels in the cerebrospinal fluid (CSF) compared with healthy controls (HC); (2) clinical and neuropsychological assessment, which included Consortium to Establish a Registry for Alzheimer’s Disease neuropsychological assessment battery (CERAD-NAB); (3) [(18)F]FBB and [(18)F]FDG PET imaging within an average of 3 weeks. The subjects were within 15 days stratified using PET, CSF measurements as HC, mild cognitive impaired (MCI) and dementia including Alzheimer´s disease. The predictive dementia-related cognitive decline values were supporting the measurements. PET images were evaluated visually and quantitatively using standard uptake value ratios (SUVR). Twenty-one (52.5%) subjects were amyloid-positive (Aβ+), with a median neocortical SUVR of 1.80 for AD versus 1.20 relative to the respective 19 (47.5 %) amyloid-negative (Aβ-) subjects. Moreover, the [(18)F]FDG and [(18)F]FBB confirmed within a sub-group of 10 patients a good complimentary role by correlation between amyloid pathology and brain glucose metabolism in 8 out of 10 subjects. The results suggest the clinical relevance for [(18)F]FBB combined with [(18)F]FDG PET retention and CFS measurements serving the management of our patients with dementia. Therefore, [(18)F]FBB combined with [(18)F]FDG PET is a helpful tool for differential diagnosis, and supports the patients’ management as well as treatment.
format Online
Article
Text
id pubmed-7956266
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79562662021-03-15 Clinical Relevance of [(18)F]Florbetaben and [(18)F]FDG PET/CT Imaging on the Management of Patients with Dementia Librizzi, Damiano Cabanel, Nicole Zavorotnyy, Maxim Riehl, Elisabeth Kircher, Tilo Luster, Markus Hooshyar Yousefi, Behrooz Molecules Article PET of β-Amyloid plaques (Aβ) using [(18)F]florbetaben ([(18)F]FBB) and [(18)F]fluorodeoxyglucose ([(18)F]FDG) increasingly aid clinicians in early diagnosis of dementia, including Alzheimer’s disease (AD), frontotemporal disease, dementia with Lewy bodies, and vascular dementia. The aim of this retrospective analysis was to evaluate clinical relevance of [(18)F]FBB, [(18)F]FDG PET and complimentary CSF measurements in patients with suspected dementia. In this study, 40 patients with clinically suspected or history of dementia underwent (1) measurement of Aβ peptides, total tau, and p-tau protein levels in the cerebrospinal fluid (CSF) compared with healthy controls (HC); (2) clinical and neuropsychological assessment, which included Consortium to Establish a Registry for Alzheimer’s Disease neuropsychological assessment battery (CERAD-NAB); (3) [(18)F]FBB and [(18)F]FDG PET imaging within an average of 3 weeks. The subjects were within 15 days stratified using PET, CSF measurements as HC, mild cognitive impaired (MCI) and dementia including Alzheimer´s disease. The predictive dementia-related cognitive decline values were supporting the measurements. PET images were evaluated visually and quantitatively using standard uptake value ratios (SUVR). Twenty-one (52.5%) subjects were amyloid-positive (Aβ+), with a median neocortical SUVR of 1.80 for AD versus 1.20 relative to the respective 19 (47.5 %) amyloid-negative (Aβ-) subjects. Moreover, the [(18)F]FDG and [(18)F]FBB confirmed within a sub-group of 10 patients a good complimentary role by correlation between amyloid pathology and brain glucose metabolism in 8 out of 10 subjects. The results suggest the clinical relevance for [(18)F]FBB combined with [(18)F]FDG PET retention and CFS measurements serving the management of our patients with dementia. Therefore, [(18)F]FBB combined with [(18)F]FDG PET is a helpful tool for differential diagnosis, and supports the patients’ management as well as treatment. MDPI 2021-02-26 /pmc/articles/PMC7956266/ /pubmed/33652938 http://dx.doi.org/10.3390/molecules26051282 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Librizzi, Damiano
Cabanel, Nicole
Zavorotnyy, Maxim
Riehl, Elisabeth
Kircher, Tilo
Luster, Markus
Hooshyar Yousefi, Behrooz
Clinical Relevance of [(18)F]Florbetaben and [(18)F]FDG PET/CT Imaging on the Management of Patients with Dementia
title Clinical Relevance of [(18)F]Florbetaben and [(18)F]FDG PET/CT Imaging on the Management of Patients with Dementia
title_full Clinical Relevance of [(18)F]Florbetaben and [(18)F]FDG PET/CT Imaging on the Management of Patients with Dementia
title_fullStr Clinical Relevance of [(18)F]Florbetaben and [(18)F]FDG PET/CT Imaging on the Management of Patients with Dementia
title_full_unstemmed Clinical Relevance of [(18)F]Florbetaben and [(18)F]FDG PET/CT Imaging on the Management of Patients with Dementia
title_short Clinical Relevance of [(18)F]Florbetaben and [(18)F]FDG PET/CT Imaging on the Management of Patients with Dementia
title_sort clinical relevance of [(18)f]florbetaben and [(18)f]fdg pet/ct imaging on the management of patients with dementia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956266/
https://www.ncbi.nlm.nih.gov/pubmed/33652938
http://dx.doi.org/10.3390/molecules26051282
work_keys_str_mv AT librizzidamiano clinicalrelevanceof18fflorbetabenand18ffdgpetctimagingonthemanagementofpatientswithdementia
AT cabanelnicole clinicalrelevanceof18fflorbetabenand18ffdgpetctimagingonthemanagementofpatientswithdementia
AT zavorotnyymaxim clinicalrelevanceof18fflorbetabenand18ffdgpetctimagingonthemanagementofpatientswithdementia
AT riehlelisabeth clinicalrelevanceof18fflorbetabenand18ffdgpetctimagingonthemanagementofpatientswithdementia
AT kirchertilo clinicalrelevanceof18fflorbetabenand18ffdgpetctimagingonthemanagementofpatientswithdementia
AT lustermarkus clinicalrelevanceof18fflorbetabenand18ffdgpetctimagingonthemanagementofpatientswithdementia
AT hooshyaryousefibehrooz clinicalrelevanceof18fflorbetabenand18ffdgpetctimagingonthemanagementofpatientswithdementia